Drugs in Tuberculosis and Leprosy

Meenakshi R. Ramanathan, Crystal K. Howell, James M. Sanders

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.

Original languageEnglish (US)
Title of host publicationSide Effects of Drugs Annual
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Number of pages14
ISBN (Print)9780444641199
StatePublished - Jan 1 2018
Externally publishedYes

Publication series

NameSide Effects of Drugs Annual
ISSN (Print)0378-6080


  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Drug guides
  • Pharmacology (medical)


Dive into the research topics of 'Drugs in Tuberculosis and Leprosy'. Together they form a unique fingerprint.

Cite this